Latest Articles
- Evolving paradigms in hypertension management: Fixed-dose single-pill combinations and future therapies
Despite the availability of effective medications, blood pressure control rates have declined over the past decade, underscoring the need for improved treatment approaches.
- Does my patient need testing for PFAS ‘forever chemicals’?
Any patient has the right to undergo blood testing for PFAS, but the limitations of testing must be discussed with the patient.
- Should I consider single-pill combination antihypertensive therapy for my patient with high blood pressure?
For many patients, starting treatment with a single-pill combination should be considered for the initial management of hypertension.
- Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce
Early trials suggested a link between GLP-1 receptor agonists and pancreatitis, but recent large meta-analyses do not support a class-wide risk.
- Newer diabetes drugs: Surprising shared benefits and unique side effects
The shared beneficial effects of the SGLT2 inhibitors and the GLP-1 receptor agonists, drugs with distinct mechanisms of action, may have an anti-inflammatory explanation.
- Breast cancer risk and screening for transgender and gender-diverse individuals
Evidence on breast cancer risk in transgender and gender-diverse individuals is limited, and recent guidelines are primarily based on expert consensus, retrospective cohort studies, and extrapolation from cisgender populations.
- Insights from the LAAOS III trial of left atrial appendage occlusion to prevent stroke in atrial fibrillation
Left atrial appendage occlusion added to routine cardiac surgery reduced the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation and high stroke risk, but questions remain.